Pricing Becomes Crucial Factor For Novo Nordisk’s Growth

The Danish diabetes drug maker is a commanding player in the market, but pushback from reimbursement authorities around the world is placing the company’s future growth prospects under scrutiny.

More from Market Access

More from Pink Sheet